Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
- PMID: 17317308
- DOI: 10.1016/j.ejheart.2006.11.006
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
Abstract
Background: Bundle branch block (BBB) is a powerful independent predictor of cardiovascular mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood.
Methods: The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomised 7599 patients with symptomatic HF to receive candesartan or placebo. The primary outcome comprised cardiovascular death or HF hospitalisation. The relative risk conveyed by BBB relative to a normal electrocardiogram was examined.
Results: The prevalence of BBB was significantly lower in patients with preserved compared with reduced systolic function (CHARM-Preserved 14.4%, Alternative 29.6%, Added 30.5%), p<0.0001. Overall, the adjusted hazard ratio for the primary outcome was 1.48 (95% confidence interval 1.22-1.78), p<0.0001, reflecting increased risk in patients with reduced LVEF (1.72 [1.28-2.31], p=0.0003). The apparently more modest risk among patients with HF-PSF was significant in unadjusted (1.80 [1.37-2.37], p<0.0001) but not adjusted analysis (1.16 [0.88-1.54], p=0.2897). However, no formal statistical difference was observed between the two cohorts, and interpretation is limited by the unknown prevalence of left and right BBB morphologies in each. Comparing BBB presence with absence yielded qualitatively similar results.
Conclusion: The simple clinical finding of BBB is a powerful independent predictor of worse clinical outcomes in patients with HF and reduced LVEF. It is less frequent, with a more modest predictive effect, in patients with preserved systolic function.
Similar articles
-
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.Heart. 2007 Jan;93(1):59-64. doi: 10.1136/hrt.2005.083949. Epub 2006 Sep 4. Heart. 2007. PMID: 16952975 Free PMC article. Clinical Trial.
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.Eur Heart J. 2008 Dec;29(24):3022-8. doi: 10.1093/eurheartj/ehn476. Epub 2008 Nov 5. Eur Heart J. 2008. PMID: 18987098 Clinical Trial.
-
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.J Hypertens Suppl. 2006 Mar;24(1):S3-7. doi: 10.1097/01.hjh.0000220400.08128.fa. J Hypertens Suppl. 2006. PMID: 16601570 Clinical Trial.
-
Angiotensin inhibition in heart failure.J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. doi: 10.3317/jraas.2004.019. J Renin Angiotensin Aldosterone Syst. 2004. PMID: 15526237 Review.
-
The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.Expert Rev Cardiovasc Ther. 2009 Jan;7(1):9-16. doi: 10.1586/14779072.7.1.9. Expert Rev Cardiovasc Ther. 2009. PMID: 19105762 Review.
Cited by
-
Combined assessment of myocardial damage and electrical disturbance in chronic heart failure.World J Cardiol. 2017 May 26;9(5):457-465. doi: 10.4330/wjc.v9.i5.457. World J Cardiol. 2017. PMID: 28603594 Free PMC article.
-
Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender.Ann Noninvasive Electrocardiol. 2012 Apr;17(2):113-22. doi: 10.1111/j.1542-474X.2012.00492.x. Ann Noninvasive Electrocardiol. 2012. PMID: 22537329 Free PMC article.
-
Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis.Ann Noninvasive Electrocardiol. 2020 Jan;25(1):e12710. doi: 10.1111/anec.12710. Epub 2019 Oct 11. Ann Noninvasive Electrocardiol. 2020. PMID: 31603593 Free PMC article.
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2021 May 22;5(5):CD012721. doi: 10.1002/14651858.CD012721.pub3. Cochrane Database Syst Rev. 2021. PMID: 34022072 Free PMC article.
-
Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction.Int J Cardiol Heart Vasc. 2025 Jan 24;57:101622. doi: 10.1016/j.ijcha.2025.101622. eCollection 2025 Apr. Int J Cardiol Heart Vasc. 2025. PMID: 39925773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous